Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc)(Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc))

概要

基本信息

药物类型

联合疫苗、预防性疫苗

别名

Measles mumps and rubella virus vaccine、Measles, Mumps and Rubella Vaccine, Live、Measles, Mumps and Rubella Virus Vaccine Live

+ [4]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

GlaxoSmithKline LLCGlaxoSmithKline GmbH & Co. KG

非在研机构

GSK Plc

最高研发阶段批准上市

首次获批日期

德国 (1998-05-31)

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

29

项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的临床试验

NCT06855160

/ Not yet recruiting临床3期

A Phase 3a, Open-Label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and Priorix Compared With Subcutaneous Administration of Varivax and Priorix, When Given as a First Dose to Healthy Children 12 to 15 Months of Age

This study aims to assess the immune response and safety of GSKs candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Mercks chickenpox vaccine, administered just under the skin, to determine which method is more effective. Additionally, the study will evaluate the immune response and safety of giving the GSK vaccines along with other childhood vaccines through a muscle injection.

开始日期2025-04-21

申办/合作机构

GSK Plc

NCT06824181

/ Recruiting临床3期

A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 4-arm Study to Investigate the Mixed Vaccination Schedules of a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) when it is given after 1 dose, 2 doses, or 3 doses of a licensed 20-valent pneumococcal vaccine compared to when 20-valent pneumococcal vaccine is given as a complete series in infants aged from approximately 2 months (42 to 89 days).
The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age (MoA). Routine pediatric vaccines will be given as per local recommendations.
There will be 6 study visits:
Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age until 15 months of age, V06 separated from V05 by 30 days.

开始日期2025-02-27

申办/合作机构

Sanofi

CTRI/2024/11/077318

/ Not yet recruiting临床4期

A phase IV, double blind, randomized, active control clinical studycomparing safety and immunogenicity of SII-Measles-Mumps-Rubella vaccine with PRIORIX (GSK) in healthy infants in India - MMR01/23

开始日期2024-12-10

申办/合作机构

Serum Institute of India Pvt Ltd.

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的临床结果

登录后查看更多信息

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的转化医学

登录后查看更多信息

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的专利（医药）

登录后查看更多信息

108

项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的文献（医药）

2023-01-01·Dermatology (Basel, Switzerland)

Intralesional Measles, Mumps, Rubella Vaccine versus Tuberculin Purified Protein Derivative Injections in the Treatment of Palmoplantar and Periungual Warts: A Double-Blind Randomized Controlled Trial

Article

作者: Anuntrangsee, Tanaporn ; Pomsoong, Cherrin ; Kositkuljorn, Chaninan ; Rutnin, Suthinee ; Thadanipon, Kunlawat ; Namasondhi, Amornrut

Background: Palmoplantar and periungual warts tend to be recalcitrant. Intralesional immunotherapy can provide high efficacy with additional benefit to distant warts. However, evidence on comparative effects between intralesional immunotherapy with measles, mumps, rubella vaccine (MMR) and tuberculin purified protein derivative (PPD) and roles of dermoscopy in predicting treatment outcomes in palmoplantar/periungual warts is limited. Objectives: The study aimed to compare efficacy and safety of intralesional MMR and PPD injections in treatment of palmoplantar/periungual warts and explore associations between dermoscopic findings and treatment outcomes. Methods: We conducted a double-blind randomized controlled trial involving 40 patients with palmoplantar/periungual warts who were equally assigned to receive MMR or PPD. Intralesional injection was done every 2 weeks until clearance or maximum of 5 treatments. Results: Complete resolution was higher in MMR than PPD group (90.0% vs. 80.0% in index lesion and 81.3% vs. 54.6% in distant lesions, respectively), although the differences were statistically nonsignificant. Dermoscopic findings were not significantly associated with complete resolution. Local swelling, i.e., the most common adverse event, occurred more frequently in PPD (40.0%) than MMR group (10.0%). Conclusion: This study suggests that intralesional immunotherapy with either MMR or PPD is efficacious in palmoplantar/periungual warts, with MMR showing a trend toward higher clearance and lower adverse events.

2022-12-01·BMC pregnancy and childbirth

Maternal mortality in the Middle East and North Africa region – how could countries move towards obstetric transition stage 5?

Article

作者: Jithesh, Anupama ; Cheema, Sohaila ; Mamtani, Ravinder ; Doraiswamy, Sathyanarayanan ; Maisonneuve, Patrick

Abstract:

Background:

Maternal mortality in the Middle East and North Africa (MENA) region decreased significantly between 1990 and 2017. This was uneven, however, with some countries faring much better than others.

Methods:

We undertook a trend analysis of Maternal Mortality Ratios (MMRs) of countries in the region in order to understand differences in reduction across countries. Data were extracted from several databases for 23 countries and territories in the region on measures of women’s empowerment, availability of vehicles and human resources for health (as a proxy to the three delays model). We identified factors associated with MMR by grouping countries into five different Stages (I-V) of obstetric transition from high to low MMRs.

Results:

Among the four Stage II countries, MMR is associated with “antenatal care coverage (% with at least one visit)” and “medical doctors per 10,000 population”. Among the eight Stage III countries, MMR is associated with “Gender Parity Index in primary and secondary level school enrolment” and with “nursing and midwifery personnel per 10,000 population”. Among the 10 countries and one territory in Stages IV and V, MMR is associated with “GDP per capita”, “nursing and midwifery personnel”, and “motor vehicle ownership/motorization rate”. Two factors were associated with changes in MMR from the period 2006–2010 to 2011–2015: 1) change in adolescent birth rate (r = 0.90,p = 0.005) and 2) Gender Parity Index in primary level school enrolment (r = − 0.51,p = 0.04).

Conclusion:

Though impressive reductions in MMR have been achieved across countries in the MENA region since 1990, governments should realize that there exists an opportunity to learn from each other to bring MMRs as close to zero as possible. Immediate steps in the right direction would include investment in human resources for health, particularly nurses and midwives; measures to improve adolescent sexual and reproductive health; and greater investments in achieving gender equity in education.

2022-12-01·Public health in practice (Oxford, England)

Design and implementation of tailored intervention to increase vaccine acceptance in a Somali community in Stockholm, Sweden - based on the Tailoring Immunization Programmes approach

Article

作者: Kulane, Asli ; Rubin, Johanna ; Habersaat, Katrine Bach ; Godoy-Ramirez, Karina ; Lindstrand, Ann ; Nejat, Sahar ; Appelqvist, Emma ; Karregård, Susanne ; Jama, Asha ; Jackson, Cath ; Butler, Robb

Objectives:

Sweden has had a high and stable vaccination coverage for measles-mumps-rubella (MMR) vaccine (>96%) through the national immunization program (NIP), but coverage rates highlight local pockets of lower vaccination coverage. This project addressed low MMR vaccine acceptance among parents in a Somali community, in Stockholm. The objective of the intervention was to increase vaccine confidence and MMR-vaccine uptake and also to inform practices addressing vaccine acceptance.

Study design:

This paper describes the design and implementation of a multi-component intervention based on the Tailoring Immunization Programmes (TIP) approach, developed by the WHO European Regional Office.

Methods:

The theoretical underpinning of TIP is the Capability, Opportunity, and Motivation Model (COM-B model) and Behaviour Change Wheel framework (BCW), adapted for vaccination. The COM-model was used to identify barriers and drivers to vaccination and intervention types. The TIP-phases described in this paper are: pre-TIP (planning), three succeeding TIP phases (situational analysis, formative research, intervention design) and the post-TIP phase (implementation).

Results:

The situation analysis and formative research revealed that parents feared the MMR vaccine due to autism or that their child would stop talking following vaccination, despite lack of scientific evidence for an association between autism and MMR vaccines. Barriers were linked to their associated COM-B factors and mapped to appropriate intervention types for two target groups: Somali parents and nurses at the Child Health Centres (CHC). Selected intervention types targeting parents were education, persuasion and modelling whereas education and training were selected for CHC nurses. The intervention activities included community engagement for parents, while the activities for nurses focused on improving encounters and dialogue with parents having low vaccine acceptance. Following the intervention design the activities were developed, pilot tested and implemented.

Conclusion:

This study confirm that the TIP approach is valuable for guiding a stepwise working process for a thorough understanding of barriers and drivers for MMR vaccination among parents in this Somali community. It facilitated the design of a theory and evidence-informed intervention targeting parents and nurses.

13

项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的新闻（医药）

2025-01-24

·drugs

COVID Vaccine Hesitancy Reducing Childhood Vaccinations

FRIDAY, Jan. 24, 2025 -- Hesitancy over the COVID-19 vaccine is leading some parents to skip important vaccinations for their children. Young children of parents who declined the COVID vaccine are about 25% less likely to get the standard measles/mumps/rubella (MMR) vaccine, researchers reported in a new study published recently in the American Journal of Public Health . Public health officials are worried that a decline in vaccine coverage will cause an increase in highly contagious childhood diseases like measles . Last year, 16 measles outbreaks were reported, compared with four outbreaks reported in 2023, according to the U.S. Centers for Disease Control and Prevention (CDC). “In the United States, we are experiencing a concerning resurgence of childhood vaccine-preventable diseases,” researcher Dr. Ben Rader , a computational epidemiologist with Boston Children’s Hospital, said in a news release. “Our research suggests that COVID-19 vaccine hesitancy has fueled increasing MMR vaccine hesitancy, leaving children more vulnerable to highly contagious and life-threatening illnesses like measles,” he added. For the study, researchers analyzed responses from nearly 20,000 parents of children younger than 5 to a digital health survey conducted from July 2023 to April 2024. Children of parents who got at least one COVID jab had higher MMR vaccination rates -- nearly 81%, compared to just under 61% for children of unvaccinated parents, researchers found. Politics also played a role in childhood vaccinations. Republican parents were 27% less likely to have their kids get the MMR vaccine than Democratic parents. “Our research highlights the link between parental characteristics and MMR vaccine uptake, showing how pandemic-related hesitancy may affect other routine vaccines,” lead researcher Eric Zhou , a pediatrics instructor at the Icahn School of Medicine at Mount Sinai in New York City, said in a news release. Overall, MMR vaccination rates were higher in the Midwest and Northeast than in the South or West. Parents on Medicare or Medicaid were about 15% less likely to have their kids get the MMR jab than parents with private insurance, results show. “Addressing these disparities, through equitable access and fostering trust and transparency in vaccine safety, is key to protecting children from preventable diseases like measles,” Zhou concluded. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

疫苗

2024-12-02

·Endpoints

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Former FDA Commissioner Scott Gottlieb opposed President-elect Donald Trump’s choice to lead the Department of Health and Human Services, saying Robert F. Kennedy Jr.’s policies would lead to a resurgence of preventable diseases and cost lives. Gottlieb led the FDA in the first Trump administration. In comments on CNBC Friday, he called Kennedy (widely known as RFK Jr.) a “committed” anti-vaccine advocate who, if confirmed by the Senate, could easily take steps to decrease the use of vaccines in the US. “I have deep concerns about Kennedy’s stated intentions to roll back core public health protections, particularly as it relates to childhood vaccines,” Gottlieb said. “I think if RFK follows through on his intentions, and I believe he will and I believe he can, it will cost lives in this country.” He said he had raised his objections with Republican senators who will vote on the selection of Kennedy, who Trump announced last month . Trump’s pick of Kennedy has been followed by a series of announcements that would put skeptics of longstanding US healthcare and public health policy in positions of power. Along with Kennedy, that includes Trump’s choice to lead the National Institutes of Health (Stanford researcher and Covid policy skeptic Jay Bhattacharya) and the CDC (former congressman Dave Weldon). While in Congress, Weldon pushed for significant changes to vaccine policy that have been sought by vaccine skeptics. Kennedy has questioned the use of childhood vaccines for years, attempting to link them to the rise of autism and raising other questions about their safety. While his remarks on his exact plans have shifted over time, at their core is the idea that he wants to push away from a policy of vaccine requirements — meant to create widespread immunity and protect those who can’t be vaccinated or who have immune issues — and create a policy of individual choice. “I’m not going to take away anybody’s vaccines,” Kennedy said in a television interview last month. “People can make individual assessments about whether that product is good for them.” The Trump transition team didn’t immediately respond to a request for comment. Gottlieb in particular warned about a resurgence of measles, a highly infectious disease that can be deadly in young children. Vaccination rates of the measles, mumps and rubella (MMR) vaccine have fallen in some parts of the country, and been followed by occasional outbreaks. Nationally, kindergarten vaccination rates are around 92% with two doses of MMR vaccine, according to a CDC study published this year . But in some states, they are far lower. In Idaho, only about 80% of children have received the vaccine. In Wisconsin, the rate is 85%. Those rates are below the 95% target the CDC says is a benchmark for creating population-level immunity to the disease. “If we lose another 5%, we’re going to see a situation where we see distributed outbreaks,” Gottlieb said. “What I worry about is that we’re at a tipping point where we’re going to see epidemics of diseases that have long been vanquished.”

疫苗

2024-03-12

·生物制品圈

2024年美国免疫实践咨询委员会≥19岁成人疫苗推荐免疫程序

2023年10月，美国免疫实践咨询委员会（ACIP）批准了2024年美国≥19岁成人疫苗推荐免疫程序。该程序每年发布一次，以整合和总结ACIP关于成人疫苗接种建议的更新，并协助医疗保健提供者实施当前的ACIP建议。ACIP关于每种疫苗使用的建议是在对疫苗相关数据进行深入分析后制定，这些数据包括疾病流行病学和社会影响、疫苗效力和有效性、疫苗安全性、证据质量、项目实施的可行性、对健康公平的影响以及免疫政策的经济分析。概述012024年≥19岁成人疫苗推荐免疫程序中针对特定疫苗的变化包括对呼吸道合胞病毒疫苗（RSV）、流感疫苗、COVID-19疫苗、灭活脊髓灰质炎病毒疫苗（IPV）、猴痘疫苗（Mpox）和脑膜炎球菌A、B、C、W、Y血清群五价疫苗（MenACWY- TT/MenB-FHbp）。其他变化包括说明了甲型肝炎疫苗（HepA）、乙型肝炎疫苗（HepB）、人乳头瘤病毒疫苗（HPV）、麻疹、腮腺炎和风疹联合疫苗（MMR）、肺炎球菌疫苗以及破伤风、白喉和百日咳疫苗（Tdap）的建议。01表1.成人免疫程序推荐的疫苗疫苗缩写商品名称新冠疫苗1vCOV-mRNAComirnaty®/辉瑞-BioNTech新冠肺炎疫苗Spikevax®/莫德纳新冠肺炎疫苗1vCOV-aPSNovavax新冠疫苗b型流感嗜血杆菌疫苗HibActHIB®Hiberix®PedvaxHIB®甲型肝炎疫苗HepAHavrix®Vaqt®甲型肝炎和乙型肝炎疫苗HepA-HepBTwinrix®乙型肝炎疫苗HepBEngerix-B®Heplisav-B®PreHevbrio®Recombivax HB®人乳头瘤病毒疫苗HPVGardasil 9®流感疫苗（灭活）IIV4众多品牌流感疫苗（活疫苗、减毒疫苗）LAIV4FluMist® Quadrivalent流感疫苗（重组）RIV4Flublok® Quadrivalent麻疹、腮腺炎和风疹疫苗MMRM-M-R II®Priorix®脑膜炎球菌A、C、W、Y血清群疫苗MenACWY-CRM MenACWY-TTMenveo®MenQuadfi®B血清群脑膜炎球菌疫苗MenB-4CMenB-FHbpBexsero®Trumenba®A、B、C、W、Y血清群脑膜炎球菌疫苗MenACWY-TT/MenB-FHbpPenbraya™猴痘疫苗MpoxJynneos®肺炎球菌结合疫苗PCV15PCV20Vaxneuvance™Prevnar 20™肺炎球菌多糖疫苗PPSV23Pneumovax 23®脊髓灰质炎病毒疫苗IPVIpol®呼吸道合胞病毒疫苗RSVArexvy®Abrysvo™破伤风和白喉类毒素疫苗TdTenivac®Tdvax™破伤风白喉类毒素和无细胞百日咳疫苗TdapAdacel®Boostrix®水痘疫苗VARVarivax®重组带状疱疹疫苗RZVShingrix02表2.2024年美国按年龄组分列的推荐成人免疫接种时间表03 表3.按医疗状况或其他迹象分列的推荐成人免疫接种时间表，美国，2024年疫苗说明02• 新的“附加信息”部分现在增加了2024年成人免疫计划的注释部分。• COVID-19：现在建议所有成年人至少接种1剂更新的（2023-2024年组分）COVID-19疫苗。所需的剂次数和剂次间隔可能因患者既往疫苗接种史、免疫功能低下状态和使用的疫苗产品而异。此外，COVID-19说明部分分为“常规疫苗接种”部分和“特殊情况”部分，前者描述了针对普通人群的疫苗接种建议，后者描述了针对中度或重度免疫功能低下人群的疫苗接种建议。• HepA：为了更好地与ACIP政策保持一致，“常规疫苗接种”部分的项目符号被修改为“任何未完全接种疫苗并要求接种疫苗的人”。• HepB：在“常规疫苗接种”部分，在描述针对≥60岁人群的基于风险的疫苗接种建议的项目符号中添加了额外的背景和细节。此外，在“常规疫苗接种”部分的末尾增加了一个注释，描述了对≥60岁糖尿病患者的共同临床决策建议。• HPV：在“常规疫苗接种”部分，删除了关于未按免疫程序完成接种的指南。当使用推荐的接种间隔完成全程HPV疫苗接种后，不建议额外剂次。• 流感：在“特殊情况”部分，删除了所有讨论鸡蛋过敏史的部分，并在“特殊情况”部分的末尾添加了一个注释，说明有鸡蛋过敏史的人可以接种任何适宜的流感疫苗。最后，删除了描述吉兰-巴雷综合征的部分。• MMR：对“常规疫苗接种”部分进行了细微更改，以提高语言清晰度。• 脑膜炎球菌：添加了资源链接，以帮助医疗保健提供者共享MenB疫苗接种的临床决策建议。有关使用新许可的五价脑膜炎球菌疫苗（Penbraya）的信息在脑膜炎球菌注释部分的末尾提供。• 猴痘：猴痘疫苗接种是成人疫苗推荐免疫程序注释部分的新内容。列出了需要常规接种Jynneos疫苗的危险因素。有关在医疗保健提供者和孕妇中使用Jynneos的要点在Mpox注释部分的末尾提供。• 肺炎球菌：在“常规疫苗接种”和“特殊情况”部分进行了细微编辑，以明确肺炎球菌疫苗的指导和最低间隔。• 脊髓灰质炎病毒：在“常规疫苗接种”部分添加了其他背景信息。本节现在呼吁未接种疫苗或未完全接种疫苗的成年人完成3剂IPV基础免疫。增加了一份声明，指出大多数在美国出生和长大的成年人可以假设他们小时候接种了脊髓灰质炎疫苗。“特殊情况”部分介绍了对已完成三剂基础免疫接种且暴露于脊髓灰质炎病毒风险增加的成年人进行一次性、终生灭活脊灰疫苗加强剂。• 呼吸道合胞病毒：今年增加了一个新的呼吸道合胞病毒注释部分。该部分以“常规疫苗接种”部分开始，描述了美国大陆大部分地区在9月至1月妊娠32-36周期间孕妇中使用Abrysvo（辉瑞公司）的情况。此外，还指出建议母亲接种RSV疫苗或婴儿接种Nirsevimab（RSV单克隆抗体）以预防婴儿呼吸道合胞病毒下呼吸道感染。在RSV注释部分的末尾添加了一条注释，以承认某些司法管辖区的RSV季节性可能与美国大陆大部分地区不同，并且提供者应遵循公共卫生当局关于孕产妇RSV疫苗接种时间的指导，基于当地的RSV季节性。 “特殊情况”部分描述了≥60岁人群接种疫苗的共同临床决策建议;可以使用Abrysvo（辉瑞公司）或Arexvy（GSK）。此外，还添加了一个资源链接，以帮助医疗保健提供者共享RSV疫苗接种的临床决策建议。最后，增加了一个注释，列出了医疗保健提供者在考虑患者患严重RSV疾病的风险以及疫苗接种的潜在益处时应考虑的风险因素和医疗条件。• Tdap：在Tdap部分的末尾添加了一个注释，以说明在10岁时接种Tdap疫苗可算作11-12岁时常规推荐的青少年剂次。参考文献：Murthy N, Wodi AP, McNally VV, Daley MF, Cineas S. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:11–15. DOI：http://dx.doi.org.libproxy1.nus.edu.sg/10.15585/mmwr.mm7301a3识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

疫苗临床研究

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BX	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
麻疹	美国	GlaxoSmithKline LLC	2022-06-03
腮腺炎	美国	GlaxoSmithKline LLC	2022-06-03
风疹	美国	GlaxoSmithKline LLC	2022-06-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
嗜血杆菌感染	临床3期	澳大利亚	GSK Plc	2006-06-01
脑膜炎	临床3期	澳大利亚	GSK Plc	2006-06-01
水痘	临床3期	美国	GSK Plc	2003-10-06
甲型肝炎	临床3期	美国	GSK Plc	2003-10-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00226499 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹 ... 更多	5,803	Priorix-tetra™ (MMRV Group)	鹽選齋艱齋觸餘鹽憲憲 = 膚簾夢鑰繭醖構積壓餘鏇廠鏇構製蓋淵鹹膚鏇 (鏇憲製憲觸遞糧範壓壓, 廠蓋繭積齋蓋鏇夢壓獵 ~ 鏇鑰夢夢鬱積鬱膚積膚) 更多	-	2019-09-23
				Varilrix™+Priorix™ (OKAH Group)	鹽選齋艱齋觸餘鹽憲憲 = 願醖廠顧蓋廠鹽簾餘艱鏇廠鏇構製蓋淵鹹膚鏇 (鏇憲製憲觸遞糧範壓壓, 遞繭鑰齋齋繭選壓簾築 ~ 積顧艱餘淵鹹獵構醖壓) 更多
NCT01681992 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹	4,538	Priorix+Varivax+Havrix+Prevnar 13 (Inv_MMR_Min Group)	顧壓淵鑰膚鹹繭簾夢積 = 選憲糧膚築襯衊鹹蓋廠鬱選鹽願襯膚夢簾衊遞 (築鹽構蓋醖網顧積獵鹹, 襯衊網網鹹築願遞積醖 ~ 鹹鬱窪願獵繭夢壓顧窪) 更多	-	2018-08-17
				Priorix+Varivax+Havrix+Prevnar 13 (Inv_MMR_Med Group)	顧壓淵鑰膚鹹繭簾夢積 = 窪夢餘繭鏇鏇艱簾網鏇鬱選鹽願襯膚夢簾衊遞 (築鹽構蓋醖網顧積獵鹹, 窪衊觸製襯遞築鏇醖鬱 ~ 顧齋構襯鏇鏇製顧範觸) 更多
NCT00969436 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹 ... 更多	450	GSK Biological's investigational MMRV vaccine 208136 (Priorix-Tetra Group)	憲艱壓糧鬱願顧壓簾製 = 製餘選觸獵遞簾憲艱醖構艱鹹築構淵積壓廠築 (淵簾鹹獵鏇築衊襯膚簾, 齋艱醖遞簾憲壓願顧壓 ~ 製醖淵膚夢襯鑰積觸鑰) 更多	-	2017-09-25
				GSK Biological's investigational MMRV vaccine 208136+Priorix™ (Priorix/ Priorix-Tetra Group)	憲艱壓糧鬱願顧壓簾製 = 遞製窪製簾壓簾壓餘積構艱鹹築構淵積壓廠築 (淵簾鹹獵鏇築衊襯膚簾, 鏇顧膚齋醖壓積鬱鬱繭 ~ 衊簾衊壓憲憲網顧遞遞) 更多
NCT01621802 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹	4,011	ProQuad+Kinrix+M-M-R II (Com_MMR_CO Group)	構壓淵製鬱壓鬱窪鑰餘 = 鹽糧構膚顧獵夢憲鑰選醖築夢窪鹽簾範艱艱築 (膚鹽構鹹衊選簾艱遞積, 鹽網餘夢簾願獵網製顧 ~ 膚齋簾餘壓製鏇網製獵) 更多	-	2017-09-13
				Priorix (Inv_MMR_I Group)	構壓淵製鬱壓鬱窪鑰餘 = 餘憲構積簾網醖鏇餘壓醖築夢窪鹽簾範艱艱築 (膚鹽構鹹衊選簾艱遞積, 醖積觸窪窪壓鬱衊齋構 ~ 顧鬱鏇衊餘淵顧積構網) 更多
NCT02058563 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹	996	Priorix® (INV_MMR Group)	獵壓憲範餘範憲廠簾壓(齋膚夢膚鏇鏇窪齋觸願) = 廠積範蓋網蓋繭選衊襯蓋選顧鬱範餘窪鬱遞範 (鑰觸醖遞窪鬱繭觸製遞, 顧築製蓋範齋遞襯鹹築 ~ 膚構鏇簾憲築範選膚餘) 更多	-	2017-04-10
				Merck's M-M-R®II, Measles, Mumps, (COM_MMR Group)	獵壓憲範餘範憲廠簾壓(齋膚夢膚鏇鏇窪齋觸願) = 積憲遞築餘齋觸廠顧糧蓋選顧鬱範餘窪鬱遞範 (鑰觸醖遞窪鬱繭觸製遞, 廠鹽繭鬱憲膚醖鬱觸窪 ~ 鑰鏇醖繭蓋蓋壓簾廠築) 更多
NCT00381615 (CTgov)	临床2期	-	147	rMenB+DTaP-Hib-IPV+MenC-CRM+MMR+MenC-Hib+PC7 (rMenB)	簾衊壓淵餘觸製鹽齋蓋 = 鹹襯繭鹽膚廠鬱鏇蓋繭淵構鹽簾繭廠鬱獵願鑰 (製窪繭鏇選艱鹹齋衊淵, 艱蓋製醖廠鏇觸積壓鹹 ~ 遞鏇壓糧鬱餘選繭蓋膚) 更多	-	2015-10-09
				DTaP-Hib-IPV+rMenB+OMV+MenC-CRM+MMR+MenC-Hib+PC7 (rMenB+OMV)	簾衊壓淵餘觸製鹽齋蓋 = 遞餘網遞餘築遞鬱構窪淵構鹽簾繭廠鬱獵願鑰 (製窪繭鏇選艱鹹齋衊淵, 鏇製鏇簾醖範鹹蓋餘廠 ~ 膚積夢獵襯觸糧醖艱壓) 更多
NCT00134719 (CTgov)	临床2期	脑膜炎 \| 嗜血杆菌感染	1,104	MenHibrix (Hib-MenCY-TT)+M-M-R®II+Varivax®+Prevenar®+Infanrix® Penta (MenHibrix Group)	築壓憲壓醖窪艱簾網淵 = 膚鹹餘觸築淵窪醖艱壓獵鬱淵築積遞簾憲鑰壓 (願網醖糧淵繭齋廠糧願, 選醖醖壓膚獵壓願鬱鏇 ~ 蓋艱顧觸艱網鏇襯餘遞) 更多	-	2012-07-20
				ActHIB®+MenHibrix (Hib-MenCY-TT)+M-M-R®II+Varivax®+Prevenar®+Infanrix® Penta+Meningitec® (ActHIB + Meningitec Group)	襯艱顧餘選鬱鏇願壓獵 = 範夢廠衊壓遞積積淵繭廠齋醖廠鏇製網蓋壓築 (淵糧鹹選壓艱襯顧鬱鹹, 觸糧憲艱淵選積構願願 ~ 襯廠獵糧憲鏇淵鏇蓋廠) 更多
NCT00861744 (CTgov)	临床2期	甲型肝炎 \| 风疹 \| 腮腺炎 ... 更多	1,259	GSK Biological's investigational vaccine 209762+Varivax®+Havrix®+Prevnar® (Priorix 1 Group)	齋壓簾窪鬱簾壓膚蓋襯 = 築鬱鏇簾築製衊襯窪醖壓廠壓餘繭積築憲糧鹽 (膚襯淵簾範壓網獵艱鏇, 餘襯窪積繭鬱衊製夢積 ~ 膚憲製繭製鹹顧鏇膚蓋) 更多	-	2011-11-04
				GSK Biological's investigational vaccine 209762+Varivax®+Havrix®+Prevnar® (Priorix 2 Group)	齋壓簾窪鬱簾壓膚蓋襯 = 廠繭範淵餘醖築壓壓艱壓廠壓餘繭積築憲糧鹽 (膚襯淵簾範壓網獵艱鏇, 襯窪糧網願構網鏇鬱淵 ~ 淵糧選衊廠夢簾選膚衊) 更多
NCT00197015 (CTgov)	临床3期	甲型肝炎 \| 风疹 \| 腮腺炎 ... 更多	1,474	Havrix® (HAV Group)	選壓網鹹構憲壓醖獵顧(襯鑰廠觸獵鏇繭鹽糧餘) = 襯淵憲淵襯憲襯憲壓觸觸糧顧醖鹹餘壓艱鑰糧 (衊選顧鹽簾膚製壓廠築, 蓋願糧齋積鏇壓選遞遞 ~ 鑰遞鏇夢選築餘網繭網) 更多	-	2010-04-01
				M-M-R®II+VARIVAX®+Havrix® (MMR+V→HAV Group)	願鏇鏇廠鹽衊簾淵衊鹹 = 製膚齋壓醖獵簾糧齋窪膚憲簾鹽範遞顧製淵製 (製襯顧醖夢醖鹹齋鏇鑰, 簾蓋廠範選糧繭簾廠壓 ~ 範鹹築壓鹹築選衊襯顧) 更多
NCT00326118 (CTgov)	临床3期	脑膜炎 \| 嗜血杆菌感染	433	Priorix™+Haemophilus influenzae type b (Menitorix Group)	齋壓選獵壓築淵選積網 = 顧鹹網蓋廠糧襯鹽窪襯廠齋鹹壓夢艱簾餘壓製 (憲觸遞餘願壓鹽淵範簾, 鹽壓鏇鏇鏇窪醖築範簾 ~ 獵壓糧襯築繭簾憲願繭) 更多	-	2009-10-23
				Hiberix™+Priorix™+Meningitec™ (Meningitec + Hiberix Group)	齋壓選獵壓築淵選積網 = 襯鏇獵窪觸築衊蓋構製廠齋鹹壓夢艱簾餘壓製 (憲觸遞餘願壓鹽淵範簾, 遞淵鹹積築構壓壓顧鬱 ~ 鬱淵築襯簾鏇壓夢壓壓) 更多